Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastases|Bone Metastases in Subjects With Advanced Breast Cancer
Interventions: BIOLOGICAL: Denosumab|DRUG: IV Bisphosphonates
Sponsor: Amgen